Cannabis in Adults with Cancer

Publication Date: March 13, 2024

Key Points

Key Points

  • Cannabis and/or cannabinoid access and use by adults with cancer has outpaced the science supporting their clinical use.
  • This guideline provides strategies for open, nonjudgmental communication between adults with cancer and clinicians about the use of cannabis and cannabinoids.
  • Clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment unless within the context of a clinical trial.
  • Cannabis and/or cannabinoids may improve refractory, chemotherapy-induced nausea and vomiting (CINV) when added to guideline-concordant antiemetic regimens.
    • Whether cannabis and/or cannabinoids can improve other supportive care outcomes remains uncertain.

Treatment

...reatmen...

...cal Communication and Educati...

...mendation 1.1Health systems and clinici...

....2Given the high prevalence of cannabi...

Recommendation 1.3When adults with cance...


...er Treatmen...

...ion 2.1Clinicians should recommend against use o...

...on 2.2Clinicians should recommend against use of...


...r Treatment-related Toxicity, Symptoms...

...ecommendation...

...ronabinol and nabilone] (EB, , M, Weak)...

...extract] (EB, , L, Weak)3499376...

...ndation 3.2Outside of a clinical trial, clinic...

...ecommendation 3.3Evidence remains ins...


...ng an In-depth History of Cannabis...


...mary of Recommendations Pertaining to Use of Canna...


Table 3. General Safety AwarenessHaving t...


Figure 1. Endocannabinoid Syst...


...es that cancer clinical trials are vital to infor...